IMUX Immunic Inc.

14.5
+0.02  (+0%)
Previous Close 14.48
Open 14.69
Price To Book 1.08
Market Cap 146,355,083
Shares 10,093,454
Volume 1,876
Short Ratio
Av. Daily Volume 124,201

NewsSee all news

  1. Immunic, Inc. Doses First Healthy Volunteer in its Phase 1 Clinical Program of IMU-935, a Potentially Best-in-Class RORgt Inverse Agonist

    SAN DIEGO, Sept. 18, 2019 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a clinical-stage biopharmaceutical company focused on developing potentially best-in-class, oral therapies for the treatment of chronic inflammatory

  2. Immunic, Inc. to Present Selected Available and Previously Unpublished Data Regarding Lead Program, IMU-838, at the Congress of the European Committee for Treatment and Research in Multiple Sclerosis 2019

    SAN DIEGO, Sept. 11, 2019 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a clinical-stage biopharmaceutical company focused on developing potentially best-in-class, oral therapies for the treatment of chronic inflammatory

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 interim dosing analysis September 5, 2019 noted trial to continue.
IMU-838
Ulcerative colitis
Phase 2 data due 3Q 2020.
IMU-838
Relapsing-remitting multiple sclerosis
Phase 2 trial to commence 2H 2019.
IMU-838
Crohn’s disease
Phase 1 commencement of dosing announced September 18, 2019.
IMU-935
Healthy volunteers
Phase 2 commencement of enrolment announced August 12, 2019.
IMU-838
Primary Sclerosing Cholangitis

Latest News

  1. Immunic, Inc. Doses First Healthy Volunteer in its Phase 1 Clinical Program of IMU-935, a Potentially Best-in-Class RORgt Inverse Agonist

    SAN DIEGO, Sept. 18, 2019 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a clinical-stage biopharmaceutical company focused on developing potentially best-in-class, oral therapies for the treatment of chronic inflammatory

  2. Immunic, Inc. to Present Selected Available and Previously Unpublished Data Regarding Lead Program, IMU-838, at the Congress of the European Committee for Treatment and Research in Multiple Sclerosis 2019

    SAN DIEGO, Sept. 11, 2019 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a clinical-stage biopharmaceutical company focused on developing potentially best-in-class, oral therapies for the treatment of chronic inflammatory